KOSDAQOthers188260

Sanigen

₩2,075▼ 6.74%2026-11-18 close
Market Cap
₩28.8B
Turnover
₩67,051,008
Volume
30K
Shares out.
13.9M
PER
—
PBR
—
EPS
-₩612
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sanigen: Losses Narrowing as a Food-Safety Diagnostics Firm Tests New Bio Business

Sanigen has posted operating losses for four straight years, but its quarterly revenue rose for two consecutive quarters in 2026 and operating losses narrowed. New bio businesses such as human molecular diagnostics are the next test.

  1. 1

    Revenue fell for three straight years from 2023 to 2025, reaching KRW 15.4 billion in 2025 (down 0.5% year on year).

  2. 2

    The 2025 operating loss narrowed to KRW 4.37 billion, but the operating margin remained deeply negative at -28.5%.

  3. 3

    Quarterly revenue rose from KRW 3.31 billion in Q1 2026 to KRW 4.2 billion in Q3 2026, with two consecutive increases. Q3 operating loss widened slightly from Q2.

  4. 4

    A third-party capital raise and the removal from KOSDAQ administrative issues on June 29, 2026 eased financial concerns, but total equity at end-2025 was only KRW 2.48 billion.

  5. 5

    The revenue contribution of new businesses, including human molecular diagnostics, microbiome healthcare, an endolysin-based therapeutic and a military catering diagnostic system, has not yet appeared in reported figures.

02

Business structure

Sanigen provides food-safety solutions from food production through consumption, built on microbial molecular diagnostics and next-generation sequencing (NGS) technology.

Based on Q2 2026 revenue, the business mix was products 65%, molecular diagnostics 11%, sterilization products 8%, services 8% and microbial testing 7% (per the data aggregator Butler). With products accounting for more than half of revenue, sales of food-safety diagnostic products largely drive total revenue.

Key customers are food manufacturers and distributors, and the collective catering market including military dining. The company estimates that if some 46,000 collective catering facilities across Korea introduced pre-meal self-testing, a new market worth KRW 360 billion a year in test volume would open.

Its multiplex rapid diagnostic system for military catering detects bacteria and viruses in a single test and cuts the total process to within four hours, the company said.

The technology holds NET certification from Korea's agri-food new technology program, and the company holds AOAC International and WOAH certified products. The company says it holds 45 patents related to microbial molecular diagnostics and NGS.

It is widening its scope into human molecular diagnostics and microbiome-based healthcare. In August 2026 it disclosed voluntarily that it had been selected for a K-HERO national project to develop an endolysin-based sepsis therapeutic. Revenue contribution from human diagnostics and therapeutics has not yet appeared in reported figures.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.1B-₩900M−22.4%
2025Q4—-₩1.8B—
2026Q1₩3.3B-₩900M−26.3%
2026Q2₩3.8B-₩400M−10.6%
2026Q3₩4.2B-₩400M−10.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩26.8B-₩4.1B-₩4.1B−15.3%—−221.0%
2023₩20.2B-₩6.5B-₩9.2B−32.1%−69.0%56.6%
2024₩15.4B-₩5.9B-₩6.6B−38.1%−79.6%78.2%
2025₩15.4B-₩4.4B-₩5.8B−28.5%−235.0%308.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a disclosed basis, revenue went from KRW 26.8 billion in 2022 to KRW 20.2 billion in 2023 (down 24.6% year on year), KRW 15.4 billion in 2024 (down 23.6%) and KRW 15.4 billion in 2025 (down 0.5%).

Revenue declined for three consecutive years from 2023 to 2025, with 2022 the largest year and 2025 the smallest within 2022 to 2025. The rate of decline was steep through 2024 and narrowed to 0.5% in 2025.

Operating losses were KRW 4.08 billion in 2022, KRW 6.48 billion in 2023, KRW 5.87 billion in 2024 and KRW 4.37 billion in 2025, a loss in each of the four years. The loss widened in 2023 and narrowed in 2024 and 2025.

The operating margin moved from -15.3% in 2022 to -32.1% in 2023 and -38.1% in 2024, before improving to -28.5% in 2025. Net loss attributable to controlling shareholders was KRW 4.06 billion in 2022, KRW 9.25 billion in 2023, KRW 6.56 billion in 2024 and KRW 5.82 billion in 2025.

Net loss including non-controlling interests was reported at the same amounts in each year. The debt ratio went from -221.0% in 2022, a negative value, to 56.6% in 2023 and 78.2% in 2024, then rose to 308.3% in 2025.

Total equity at end-2025 was KRW 2.48 billion against total liabilities of KRW 7.64 billion, so the thin equity base is what pushes the ratio higher. Operating cash flow was negative every year, at -KRW 3.21 billion in 2022, -KRW 3.78 billion in 2023, -KRW 5.44 billion in 2024 and -KRW 4.18 billion in 2025.

On a quarterly basis, revenue bottomed at KRW 3.31 billion in Q1 2026, then rose to KRW 3.81 billion in Q2 (up 15.2% from the prior quarter) and KRW 4.2 billion in Q3 (up 10.3% from the prior quarter and up 3.8% year on year).

Operating loss widened from KRW 908 million in Q3 2025 to KRW 1.78 billion in Q4 2025, then narrowed to KRW 872 million in Q1 2026 and KRW 405 million in Q2, before edging up to KRW 438 million in Q3.

Net loss attributable to controlling shareholders fell from KRW 3.17 billion in Q4 2025 to KRW 145 million in Q2 2026, then rose to KRW 682 million in Q3. The four quarters from Q4 2025 to Q3 2026 total KRW 4.89 billion.

Media reports attribute the quarterly loss reduction to higher-margin product sales and lower selling and administrative costs. Because losses widened again in Q3, whether the narrowing trend holds will show up in the next periodic reports.

05

Industry analysis

Sanigen's core market is food-safety testing. Growth in the food-safety testing market and rising demand for PCR- and NGS-based diagnostic products are summarized as drivers of revenue improvement, per a FnGuide company summary based on Q1 2025 results.

Tighter food-safety regulation and wider adoption of advanced molecular diagnostics are described as pushing the market to grow quickly.

In collective catering, media note that facilities freeze meal samples and use them only for after-the-fact investigation, with no legal obligation for pre-meal testing, which the company cites as its opening. The company is targeting that gap with rapid pre-meal testing.

On technology, holding the NET certification alongside AOAC International and WOAH certifications is cited as a differentiator. In food safety and human diagnostics, regulatory approval and certification act as entry barriers, so certification holdings carry weight in competition.

Human molecular diagnostics and microbiome healthcare fall within the precision medicine trend, which the company describes as essential for infectious disease diagnosis and disease prediction. Inclusion in a national defense project lines up directly with the military catering diagnostic demand. The company's market size estimate is its own figure and has not been independently verified.

06

Outlook

The company said in a first-half 2026 media report that it expects revenue of about KRW 18 billion this year and more than KRW 23 billion next year. Given disclosed quarterly revenue of KRW 3.31 billion in Q1 2026, KRW 3.81 billion in Q2 and KRW 4.2 billion in Q3, the gap to the annual target depends on Q4 results.

In defense, the company was selected in July 2026 as the lead organization for a local-government development grant program run by the Jeonbuk Defense Venture Center. The company set a goal of exhibiting its military catering diagnostic system at a Ministry of National Defense exhibition in December 2026.

It described a path to procurement registration if the product is filed as an innovative product, which would widen its procurement market. Entry into human molecular diagnostics and activation of microbiome healthcare were presented as priorities.

A plan was also reported to diversify into human diagnostics and mutation tracking systems by combining the global network of the investor that took part in the third-party capital raise with its genome analysis technology. Reports did not give revenue timing or scale for the new businesses in figures.

When the 2026 annual business report confirms full-year revenue and operating loss, the distance from the company's targets will become visible.

07

Valuation

PER
—
PBR
—
ROE
-51.0%
EPS
-₩612
BPS
—
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the company has posted net losses over the last four quarters. Measured against total equity of KRW 2.48 billion at end-2025, the market capitalization sits far above the book equity base.

Even after the third-party capital raise in the first half of 2026 added equity, the premium over book assets remains large. This suggests that expectations for business growth account for a larger share of the share price than book value does.

Historical P/E bands are of limited use as a benchmark because the loss period has been long. With operating losses in each year since 2022, business indicators such as revenue recovery and a narrower loss are a more natural starting point than earnings-based multiples. Dividends are hard to expect under a loss-making structure.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Quarterly revenue rebound and narrower losses

Quarterly revenue rose from KRW 3.31 billion in Q1 2026 to KRW 3.81 billion in Q2 and KRW 4.2 billion in Q3, with two consecutive increases. Operating loss narrowed from KRW 1.78 billion in Q4 2025 to KRW 405 million in Q2 2026, and the Q3 loss remained smaller than a year earlier. Whether a wider revenue base eases the fixed-cost burden is the central question for this trend.

Financial structure entering normalization

A third-party capital raise in the first half of 2026 secured funds, and media reported that it substantially reduced the debt ratio. The removal of the market-capitalization shortfall designation on June 29, 2026 reduced uncertainty about listing status. Compared with total equity of KRW 2.48 billion at end-2025, the stronger capital base is a positive factor.

National projects and a new-business pipeline

In July 2026 the company was selected as lead organization for a defense venture development grant program, which it said would speed its push into the military catering diagnostics market.

In August 2026 it disclosed voluntarily that an endolysin-based sepsis therapeutic had been selected for a K-HERO national project. Whether plans to expand into human molecular diagnostics and microbiome healthcare translate into revenue is the next point to watch.

09

Bear factors

Four straight years of operating losses and a thin equity base

Operating losses have occurred in each year from 2022 to 2025, and in 2025 the operating loss was KRW 4.37 billion and the net loss attributable to controlling shareholders was KRW 5.82 billion. Total equity at end-2025 was KRW 2.48 billion and the debt ratio was 308.3%.

Net losses attributable to controlling shareholders totaled KRW 4.89 billion over the last four quarters, so losses continue at the quarterly level.

Three straight years of revenue decline

Revenue declined for three consecutive years, to KRW 20.2 billion in 2023, KRW 15.4 billion in 2024 and KRW 15.4 billion in 2025. The 2025 decline narrowed to 0.5%, but it is too early to call this a return to annual growth. Whether quarterly increases in 2026 lead to an annual rebound will appear in the 2026 annual business report.

Losses widened again in Q3

Operating loss rose to KRW 438 million in Q3 2026 from KRW 405 million in Q2, and net loss attributable to controlling shareholders widened from KRW 145 million to KRW 682 million. A quarterly return to profit has not yet appeared in the disclosed figures. If losses continue, the need for further funding remains.

10

Risk factors

Financial capacity and funding

Total equity at end-2025 was KRW 2.48 billion against liabilities of KRW 7.64 billion, a thin equity base. Operating cash flow in 2025 was -KRW 4.18 billion, so cash outflows continued. If further funds are needed and another capital raise follows, existing shareholders' stakes could be diluted.

Concentration and new-business execution

Products accounted for 65% of Q2 2026 revenue, so sales are concentrated in a single product group. Human molecular diagnostics and the endolysin-based therapeutic are still at development stages, so the timing of any earnings contribution is uncertain. Heavier investment in bio businesses could slow the pace of profitability recovery in the food-safety business.

Regulation and procurement process

Military procurement registration requires an innovative-product application and review, and no timing has been set. If pre-meal testing is not mandated for collective catering facilities, the new market estimate may be hard to realize. The KRW 360 billion market figure is the company's own estimate.

11

What to watch next

  1. December 2026

    This is the target timing for exhibiting at a Ministry of National Defense exhibition. It indicates whether the military catering diagnostic system can connect to procurement.

  2. Late March 2027

    This is the filing deadline for the 2026 annual business report. It will show how full-year revenue compares with the company's expectation of about KRW 18 billion and how far the operating loss narrowed from KRW 4.37 billion in 2025.

  3. Mid-May 2027

    This is around the filing deadline for the Q1 2027 quarterly report. It shows whether the operating loss and the net loss attributable to controlling shareholders, which widened again in Q3 2026, return to a narrowing trend.

12

Overall view

Sanigen has posted operating losses since 2022, and its revenue declined for three straight years to KRW 15.4 billion in 2025. The 2025 operating loss narrowed to KRW 4.37 billion from the prior year, and the operating margin was -28.5%.

Quarterly revenue rose from KRW 3.31 billion in Q1 2026 to KRW 4.2 billion in Q3, with two consecutive increases, and operating loss narrowed from KRW 1.78 billion in Q4 2025 to KRW 405 million in Q2 2026.

However, operating loss of KRW 438 million and a net loss attributable to controlling shareholders of KRW 682 million in Q3 widened losses again, so the continuity of the narrowing is still to be confirmed.

On the financial side, the third-party capital raise and the removal from administrative issues on June 29, 2026 eased risks, but total equity of KRW 2.48 billion at end-2025 and continued operating cash outflows remain open issues.

Human molecular diagnostics, microbiome healthcare, the endolysin-based therapeutic and the military catering diagnostic system have not yet appeared in reported revenue. Whether the company reaches its expected revenue of about KRW 18 billion will be visible in the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. butler.works
  2. medicaldaily.co.kr
  3. comp.fnguide.com
  4. newstomato.com
  5. newstomato.com
  6. medipharmhealth.co.kr
  7. icouncil.kr
  8. enetnews.co.kr
  9. m.news.nate.com
  10. edaily.co.kr
  11. kr.investing.com
  12. biospace.com
  13. getnews.co.kr
  14. tradingkey.com
  15. m.news.nate.com
  16. view.asiae.co.kr
  17. kr.investing.com
  18. openpr.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.